Journal
OPEN BIOLOGY
Volume 2, Issue -, Pages -Publisher
ROYAL SOC
DOI: 10.1098/rsob.120080
Keywords
PINK1; Parkin; Parkinson's disease
Categories
Funding
- Parkinson's UK Studentship
- J. Macdonald Menzies Charitable Trust
- Wellcome Trust
- Medical Research Council
- Parkinson's UK
- Michael J. Fox Foundation for Parkinson's disease research
- Wellcome/MRC PD consortium
- Cancer Research UK
- AstraZeneca
- Boehringer-Ingelheim
- GlaxoSmithKline
- Merck KgaA
- Janssen Pharmaceutica
- Pfizer
- MRC [MC_G1000735, MC_U127070193, G1100713] Funding Source: UKRI
- Medical Research Council [MC_U127070193, MC_G1000735, 973992, G1100713] Funding Source: researchfish
- Parkinson's UK [H-1101, H-0901] Funding Source: researchfish
Ask authors/readers for more resources
Missense mutations in PTEN-induced kinase 1 (PINK1) cause autosomal-recessive inherited Parkinson's disease (PD). We have exploited our recent discovery that recombinant insect PINK1 is catalytically active to test whether PINK1 directly phosphorylates 15 proteins encoded by PD-associated genes as well as proteins reported to bind PINK1. We have discovered that insect PINK1 efficiently phosphorylates only one of these proteins, namely the E3 ligase Parkin. We have mapped the phosphorylation site to a highly conserved residue within the Ubl domain of Parkin at Ser(65). We show that human PINK1 is specifically activated by mitochondrial membrane potential (Delta psi m) depolarization, enabling it to phosphorylate Parkin at Ser(65). We further show that phosphorylation of Parkin at Ser(65) leads to marked activation of its E3 ligase activity that is prevented by mutation of Ser(65) or inactivation of PINK1. We provide evidence that once activated, PINK1 autophosphorylates at several residues, including Thr(257), which is accompanied by an electrophoretic mobility band-shift. These results provide the first evidence that PINK1 is activated following Delta psi m depolarization and suggest that PINK1 directly phosphorylates and activates Parkin. Our findings indicate that monitoring phosphorylation of Parkin at Ser(65) and/or PINK1 at Thr(257) represent the first biomarkers for examining activity of the PINK1-Parkin signalling pathway in vivo. Our findings also suggest that small molecule activators of Parkin that mimic the effect of PINK1 phosphorylation may confer therapeutic benefit for PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available